secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2025-09-10T23:59:59+00:00
Accession:  0001140361-25-034506
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics posts corporate presentation; no material financial or pipeline details provided
--------------------------------------------------------------------------------

- Updated corporate presentation posted on company website as of Sept 10, 2025.
- Presentation prepared for H.C. Wainwright Global Investment Conference in September 2025.
- Filing text and exhibit excerpt do not disclose any new financial data or pipeline milestones.
- Company focus remains anti-fibrotic therapeutics for chronic organ diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036125034506/0001140361-25-034506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036125034506/ef20055378_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-034506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer